In Cytiva BioProcess R&D AB v. JSR Corp. and JSR Life Sciences, LLC, the US Court of Appeals for the Federal Circuit found all claims challenged in six inter partes review (IPR) proceedings concerning chromatography matrices for isolating target compounds unpatentable as obvious.
Source link
Lead Compound Analysis Not Required in Obviousness Determination of Biomolecular Chromatography Claims: Federal Circuit
